Literature DB >> 33261536

Bacteriophages for ESKAPE: role in pathogenicity and measures of control.

Amrita Patil1, Rajashri Banerji1, Poonam Kanojiya1, Santosh Koratkar1, Sunil Saroj1.   

Abstract

INTRODUCTION: The quest to combat bacterial infections has dreaded humankind for centuries. Infections involving ESKAPE (Enterococcus spp., Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter spp.) impose therapeutic challenges due to the emergence of antimicrobial drug resistance. Recently, investigations with bacteriophages have led to the development of novel strategies against ESKAPE infections. Also, bacteriophages have been demonstrated to be instrumental in the dissemination of virulence markers in ESKAPE pathogens. AREAS COVERED: The review highlights the potential of bacteriophage in and against the pathogenicity of antibiotic-resistant ESKAPE pathogens. The review also emphasizes the challenges of employing bacteriophage in treating ESKAPE pathogens and the knowledge gap in the bacteriophage mediated antibiotic resistance and pathogenicity in ESKAPE infections. EXPERT OPINION: Bacteriophage infection can kill the host bacteria but in survivors can transfer genes that contribute toward the survival of the pathogens in the host and resistance toward multiple antimicrobials. The knowledge on the dual role of bacteriophages in the treatment and pathogenicity will assist in the prediction and development of novel therapeutics targeting antimicrobial-resistant ESKAPE. Therefore, extensive investigations on the efficacy of synthetic bacteriophage, bacteriophage cocktails, and bacteriophage in combination with antibiotics are needed to develop effective therapeutics against ESKAPE infections.

Entities:  

Keywords:  Bacteriophage; ESKAPE; lysogenic cycle; lytic cycle; pathogenicity; treatment

Year:  2021        PMID: 33261536     DOI: 10.1080/14787210.2021.1858800

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  2 in total

Review 1.  What Is New in the Anti-Pseudomonas aeruginosa Clinical Development Pipeline Since the 2017 WHO Alert?

Authors:  Sébastien Reig; Audrey Le Gouellec; Sophie Bleves
Journal:  Front Cell Infect Microbiol       Date:  2022-07-08       Impact factor: 6.073

2.  Isolation and characterization of a lytic bacteriophage against Pseudomonas aeruginosa.

Authors:  Sonika Sharma; Sibnarayan Datta; Soumya Chatterjee; Moumita Dutta; Jhuma Samanta; Mohan G Vairale; Rajeev Gupta; Vijay Veer; Sanjai K Dwivedi
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.